[
    [
        {
            "time": "",
            "original_text": "医疗保健：同时明确首家生物类似药为高 荐14股",
            "features": {
                "keywords": [
                    "医疗保健",
                    "生物类似药",
                    "高荐"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "保健",
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医疗保健：同时明确首家生物类似药为高 荐14股",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "医药行业2018年投资策略：正本清源柳暗花明",
            "features": {
                "keywords": [
                    "医药行业",
                    "投资策略",
                    "正本清源"
                ],
                "sentiment_score": 0.65,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药行业2018年投资策略：正本清源柳暗花明",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 3,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业:优先审评流程进一步细化,继续支持药品创新",
            "features": {
                "keywords": [
                    "医药生物",
                    "优先审评",
                    "药品创新"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业:优先审评流程进一步细化,继续支持药品创新",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        }
    ]
]